Cancer, Malaria & TB Vaccinesv
Malaria continues to claim an estimated 2 to 3 million lives annually and to cause unimaginable misery for the 300 to 500 million people who contract it on a yearly basis. Due in large part to the spread of parasite strains that are safe for treatment, the decay of the healthcare system, and difficulties in implementing and maintaining vector control programs in many developing countries, jungle fever is considered to be a reemerging disease. People get jungle fever from four different protozoan parasite types: Plasmodium falciparum, P. vivax, P. malaria, and P. oval. The majority of fatalities and the vast majority of severe illnesses, including cerebral jungle fever, are caused by P. falciparum. 2 billion people with M. tuberculosis who are inactive 5–10% of those exposed get illness. Every year, there are 9 million new cases of TB. Annual TB deaths total 1.5 million. equivalent to 20 passenger aircraft crashes each day. TB is spread by adults who have citatory illness. People with HIV worry about the illness's more serious concerns. Most extreme TB horribleness and mortality, as compared to more mature children and adults, as well as the highest risk of progression from TB contamination to active infection.
- AS01 Vaccine
- RTS, S
Related Conference of Cancer, Malaria & TB Vaccinesv
9th International Conference on Vaccines, Immunology and Clinical Trials
7th International conference on Vaccines, Vaccination and Immunization
Cancer, Malaria & TB Vaccinesv Conference Speakers
Recommended Sessions
- HIV Vaccines
- Cancer, Malaria & TB Vaccinesv
- Combination & Conjugate Vaccines
- DNA & Synthetic Vaccines
- Human Vaccines Against Infectious Diseases
- New Trends in Vaccines Development
- Pediatric Vaccines
- RDT in Antibiotic Research
- Side-effects of Vaccines
- Toxoid Vaccines
- Vaccine Production & Development
- Vaccine Safety & Efficacy
- Vaccines
- Vaccines for Pregnant Women
- Vaccines for Unconventional Diseases
- Vaccines Manufacturing Technologies
- Vaccines Research and Clinical Trails
- Zika Virus Vaccines
Related Journals
Are you interested in
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)

